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http://dx.doi.org/10.1016/j.ccr.2012.05.014SUMMARYThe proapoptotic death receptor DR5 has been studied extensively in cancer cells, but its action in the tumor
microenvironment is not well defined. Here, we uncover a role for DR5 signaling in tumor endothelial cells
(ECs). We detected DR5 expression in ECs within tumors but not normal tissues. Treatment of tumor-bearing
mice with an oligomeric form of the DR5 ligand Apo2L/TRAIL induced apoptosis in tumor ECs, collapsing
blood vessels and reducing tumor growth: Vascular disruption and antitumor activity required DR5
expression on tumor ECs but not malignant cells. These results establish a therapeutic paradigm for proa-
poptotic receptor agonists as selective tumor vascular disruption agents, providing an alternative, perhaps
complementary, strategy to their use as activators of apoptosis in malignant cells.INTRODUCTION
Apoptosis, or type I programmed cell death, is essential for
normal development, tissue homeostasis, and tumor suppres-
sion in higher organisms (Strasser et al., 2000). The ability of
the proapoptotic receptor ligand Apo2L/TRAIL (TNFSF10) to
kill malignant cells selectively has prompted an intensive effort
to explore its therapeutic potential. Various agonists of the
cognate death receptors DR4 and DR5 have been developed,
and several have been studied in human cancer clinical trials
(Ashkenazi and Herbst, 2008; Johnstone et al., 2008). Referred
to as proapoptotic receptor agonists (PARAs) (Ashkenazi,
2008a), these agents include recombinant human Apo2L/TRAIL
(dulanermin) and several agonistic antibodies targeting DR4 or
DR5. Although certain cancer cells undergo apoptosis in
response to PARAs, others exhibit partial or total resistanceSignificance
Cancer therapies typically attack the malignant cells of a tum
may augment antitumor efficacy. Various types of cancer cells
induce apoptosis of certain malignant cells and thereby can e
within tumor blood vessels can selectively express DR5. Activ
This disrupts the integrity of tumor blood vessels and decreas
the malignant cell compartment. Our findings suggest a uniqu
agonists as vascular disruption agents in cancer therapy.
80 Cancer Cell 22, 80–90, July 10, 2012 ª2012 Elsevier Inc.(Abdulghani and El-Deiry, 2010; Yang et al., 2010). Preclinical
studies with these agents have relied mainly on cultured human
cancer cells or mouse-xenografted human tumors. However,
because most PARAs target human receptors but not their
mouse counterparts (Ashkenazi, 2002), the effects of death-
receptor engagement on the tumor microenvironment are not
well understood.
Some previous studies have used MD5-1, an antibody
directed against murine DR5 (or TRAIL-R), the only Apo2L/TRAIL
death receptor present in the mouse. MD5-1 is reported to
induce apoptosis of cancer cells in vitro; however, its tumoricidal
efficacy in vivo requires aspects of innate and adaptive host
immunity (Frew et al., 2008; Haynes et al., 2010; Takeda et al.,
2004; Uno et al., 2006). Other studies have examined the ability
of Apo2L/TRAIL to induce apoptosis in endothelial cells: these
were performed mainly by in vitro culture of endothelial cellsor, but targeting the nonmalignant tumor microenvironment
express the proapoptotic death receptor DR5. DR5 agonists
xert antitumor activity. Here we show that endothelial cells
ation of DR5 on tumor endothelial cells triggers apoptosis:
es tumor growth even in the absence of DR5 expression in
e, perhaps complementary, utility for proapoptotic receptor
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Figure 1. DR5-Dependent Disruption of the
Tumor Vasculature by Apo2L/TRAIL
(A) Lewis lung carcinoma (LLC) tumors (>500mm3)
grown in WT (DR5+/+) or DR5-KO (DR5/) mice
were dosedwith an intraperitoneal (i.p.) injection of
10 mg/kg of Apo2L/TRAIL (consisting of 10 mg/kg
of Flag-tagged Apo2L/TRAIL and 10 mg/kg anti-
Flag antibody, given sequentially) or PBS. Tumors
were examined macroscopically 24 hr after treat-
ment for the appearance of vascular disruption.
(B) Hematoxylin and eosin (H&E) staining of
sections from LLC tumors grown inWT or DR5-KO
mice and treated with Apo2L/TRAIL.
(C) Anti-PLVAP staining was used to visualize the
tumor endothelium; representative images show
disrupted blood vessels (inset = higher magnifi-
cation image) in tumors from Apo2L/TRAIL-
treatedWT, but not DR5-KO or untreated (control),
mice. Scale bars, 50 mm.
(D) Immunofluorescence colocalization of DAPI
(blue), PLVAP (green), and collagen IV (red) on LLC
tumor sections from control or Apo2L/TRAIL-
treated, WT mice. Single-channel as well as
merged images are shown. Scale bar, 10 mm. Data
in Figure 1 are representative of two or more
independent experiments.
See also Figure S1.
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DR5 Activation Disrupts the Tumor Vasculatureand arrived at conflicting conclusions as to whether this ligand
induced apoptosis or proliferation in these cells (Chan et al.,
2010; Chen and Easton, 2010; Li et al., 2003). Indeed, the prevail-
ing paradigm for PARAs as anticancer therapeutics remains
centered on their ability to induce apoptosis directly in malignant
cells.
In the present study, we investigated the biological activity of
an oligomeric form of Apo2L/TRAIL capable of activating DR5 in
both the malignant and stromal compartments of tumors.
RESULTS
DR5-Dependent Disruption of the Tumor Vasculature
by Crosslinked Apo2L/TRAIL
Although murine cancer cells often express DR5, they do not
respond to dulanermin, the trimeric recombinant soluble version
of human Apo2L/TRAIL that has been studied in clinical trialsCancer Cell 22, 8(Ashkenazi et al., 1999; Herbst et al.,
2010) (Figure S1A available online; data
not shown). However, we found that
crosslinking of a Flag epitope-tagged
version of Apo2L/TRAIL with an anti-
Flag antibody into higher order oligomers
enabled the ligand to induce apoptosis
in a range of mouse cancer cell lines:
These included Renca331 cells (Fig-
ure S1B), which are particularly sensitive
to membrane-bound Apo2L/TRAIL (Seki
et al., 2003), as well as Lewis lung carci-
noma (LLC) cells (Figure S1C). To deter-
mine the efficacy of this oligomeric
DR5-ligand in vivo, we implanted LLC
cells into C57BL/6 wild-type recipientmice and treated the animals with a single dose of crosslinked
Apo2L/TRAIL (Apo2L/TRAIL hereafter). Surprisingly, we ob-
served a striking hemorrhagic appearance in tumors within
24 hr of treatment (Figure 1A). Histological examination
confirmed extensive tumor hemorrhage, as well as widespread
tumor-cell death (Figure 1B). Such effects were not induced
by dulanermin (Figure S1D), consistent with its lack of activity
toward mouse DR5. Immunohistochemical staining with the
Meca-32 antibody (Hallmann et al., 1995), which recognizes
the plasmalemma vesicle-associated protein (PLVAP; also
PV-1)—an endothelial marker—revealed severe disruption of
the tumor vasculature in response to Apo2L/TRAIL. Tumor
blood vessels in treated mice showed evidence of conges-
tion, discontinuity in ECs lining the vessel, and blood-cell
leakage (Figure 1C). To evaluate this further, we performed
immunofluorescence staining for PLVAP in conjunction with
collagen IV, a marker for the basement membrane. In tumors0–90, July 10, 2012 ª2012 Elsevier Inc. 81
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Figure 2. DR5-Mediated Apoptosis in Tumor-
Associated Endothelial Cells
(A) Top, analysis of DR5 expression by CD45lowCD31high
expressing tumor endothelial cells (ECs) in LLC tumors
grown in WT (DR5+/+) or DR5-KO (DR5/) mice. DR5
expression (shaded) versus isotype control (open) on cell
lines are shown from a pooled cell fraction generated from
WT (n = 4) or DR5-KO LLC tumors. Bottom, analysis
of DR5 expression by CD45lowCD31high expressing,
‘‘normal’’ kidney endothelial cells isolated from WT or
DR5-KO mice. Pooled kidney cell fractions were gener-
ated from the same mice that were analyzed above.
(B) Anti-PLVAP and activated capsase-3 (CC3) staining in
serial LLC tumor sections collected from WT or DR5-KO
mice treated for the indicated times with Apo2L/TRAIL or
PBS (control).
(C) Quantitation of cleaved caspase-3 immunohisto-
chemical staining on LLC tumor sections from a time
course of Apo2L/TRAIL treatment. The average of n = 5
tumors for each time point is plotted; error bars indicate
the SEM. Student’s t test was used to calculate statistical
significance. Data in Figure 2 are representative of two or
more independent experiments.
See also Figure S2.
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DR5 Activation Disrupts the Tumor Vasculaturefrom untreated mice, blood vessels were characterized by a
contiguous layer of PLVAP-positive cells within the collagen
IV-stained basement membrane (Figure 1D); in contrast,
tumors from mice treated with Apo2L/TRAIL for 24 hr dis-
played congested blood vessels, with only occasional PLVAP-
positive cells and with large areas of ‘‘naked’’ basement
membrane. These observations suggest that Apo2L/TRAIL
treatment leads to ablation and detachment of ECs lining
blood vessels within tumors, thereby perturbing the integrity
of these vessels.
DR5-Dependent Apoptosis Activation in Tumor
Endothelial Cells
Remarkably, implantation of LLC tumor cells in DR5-deficient
mice completely abrogated the effects of Apo2L/TRAIL on the
tumor vasculature (Figures 1A–1C). We therefore hypothesized
that the proapoptotic ligand might be exerting a direct biological
effect on the tumor-stromal compartment. To evaluate this
possibility, we dissociated LLC tumors grown in wild-type (WT)
or DR5-knockout (KO) recipients and stained the isolated cells
for flow cytometric analysis with antibodies to three markers:
DR5; the leukocyte common antigen, CD45; and the endothelial
cell-associated antigen, CD31 (Tang et al., 1993). We used
differential CD45 and CD31 expression to broadly define
tumor-associated leukocytes (CD45high), a tumor epithelial-cell
enriched fraction (CD45lowCD31low), and tumor ECs (CD45low82 Cancer Cell 22, 80–90, July 10, 2012 ª2012 Elsevier Inc.CD31high). We detected DR5 protein expression
on CD45lowCD31low malignant epithelial cells
from tumors grown in WT or DR5-KO mice,
but not on CD45high leukocytes from tumors
grown in mice with either DR5 genotype
(Figure S2A) (Tang et al., 1993). Importantly,
we also observed DR5 expression on CD45low
CD31high endothelial cells from tumors grown
in WT but not DR5-KO mice (Figure 2A). Bycontrast, we did not detect significant DR5 expression on
CD45lowCD31high endothelial cells isolated from the kidneys of
normal WT mice (Figure 2A). Immunohistochemistry confirmed
DR5 expression on ECs within the tumor stroma of WT mice
(Figure S2B).
ECs in various tissues are phenotypically and functionally
diverse, with differential surface-marker expression and distinct
adherens and tight junctional complexes (Dejana, 2004; Jain,
2005; Pober and Sessa, 2007). Consistent with the lack of DR5
expression by ECs in normal tissues, we did not observe any
evidence of vascular disruption or hemorrhage outside of the
tumor microenvironment in Apo2L/TRAIL-treated mice. The
apparent selectivity of DR5 expression on tumor ECs as com-
pared to normal-tissue ECsmay reflect local stressful conditions
within the tumor such as hypoxia, which has been shown to
increase DR5 expression in cancer cells (Mahajan et al., 2008).
To assess proapoptotic signaling in tumor ECs, we monitored
the appearance of apoptotic markers over time in LLC tumors
from mice treated with Apo2L/TRAIL. Serial sections of tumor
tissue were stained for PLVAP to localize tumor ECs, or with
an antibody specific to active (cleaved) caspase-3 as an indi-
cator of proapoptotic signaling. Some areas of active caspase-3
staining appeared in tumor epithelial cells regardless of treat-
ment (Figure 2B), suggesting spontaneous focal apoptosis as
is commonly seen inmouse tumors. However, we detected rapid
generation of active caspase-3 in tumor ECs, within 2 hr after
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Figure 3. Temporal Analysis of Tumor-Vascular
Changes Induced by Apo2L/TRAIL
Quantitation of anti-PLVAP immunostaining was per-
formed on tumor sections from mice treated with Apo2L/
TRAIL for the indicated time period.
(A) Vascular perimeter (presented as vessel perimeter
in mm, divided by viable area in mm2 multiplied by 100).
Horizontal bars indicate the mean ± SEM. Statistical
significance was calculated using a two-tailed, indepen-
dent samples t test.
(B) Vascular area (presented as vessel area in mm2,
divided by viable area in mm2 multiplied by 100). Vascular
perimeter and area were calculated as described in
Supplemental Experimental Procedures. Horizontal bars
indicate the mean ± SEM. Statistical significance was
calculated using a two-tailed, independent samples
t test.
(C) LLC tumor-bearing WT or DR5-KO mice (n =
3–5/group) were treated with PBS or Apo2L/TRAIL. Two hr
after treatment, mice were injected intravenously with the
fluorescent blood pool probe AngioSense680IVM. Distri-
bution of the fluorescent probe in the tumor was moni-
tored at the indicated times on anesthetized mice. Shown
are representative images from a time course following
injection of the probe.
(D) Quantification from (C). Error bars indicate the SEM.
See also Figure S3.
Cancer Cell
DR5 Activation Disrupts the Tumor VasculatureApo2L/TRAIL treatment. By 8 hr, there was evidence of vessel
congestion and hemorrhage (indicated by the presence of blood
cells outside of PLVAP-marked vascular spaces). Distinct
changes in EC morphology were also apparent, with cell bodies
rounded and protruding into the lumen (Figure 2B). By 24 hr after
Apo2L/TRAIL treatment, extensive active caspase-3 staining
could be seen throughout the tumor (Figure 2C; Figure S2C).
Remarkably, at early time points, little caspase-3 activity was
present within malignant epithelial cells (Figures 2B and 2C),
suggesting that Apo2L/TRAIL-induced apoptosis in tumor
ECs preceded, and was independent of, apoptosis in the
malignant-cell compartment. Apo2L/TRAIL did not induce
EC apoptosis in LLC tumors grown in DR5-deficient mice
(Figure S2C), confirming direct DR5-dependent signaling in
tumor ECs.
In contrast to Apo2L/TRAIL, the MD5-1 antibody, which
targets mouse DR5, did not induce discernible effects on the
tumor vasculature. LLC tumors from mice treated with MD5-1
showed no evidence of hemorrhage (Figure S2D), and activationCancer Ceof caspase-3 in these tumors by MD5-1 was
significantly weaker than stimulation by Apo2L/
TRAIL (Figure S2E). However, MD5-1 did inhibit
tumor growth in vivo (Figure S2F). These results
suggest that the enhanced potency achieved by
crosslinking of Apo2L/TRAIL, perhaps better
mimicking the transmembrane form of this
ligand, is important for activation of DR5-medi-
ated apoptosis in tumor ECs. Nevertheless,
additional mechanisms supported by MD5-1,
such as innate or adaptive immune-cell func-
tions (Frew et al., 2008; Haynes et al., 2010;
Takeda et al., 2004; Uno et al., 2006), maymediate generation of an apoptotic signal by this anti-DR5 anti-
body in tumor cells.
Temporal Analysis of DR5-Mediated Tumor-Vascular
Disruption
We next asked whether the apoptotic effects of Apo2L/TRAIL on
ECs were associated with changes in tumor-vascular density.
Using a method previously described (Brey et al., 2003), we
quantitated PLVAP immunostaining in control and Apo2L/
TRAIL-treated tumor specimens over time. By 8 hr after treat-
ment with Apo2L/TRAIL, both the vascular perimeter and area
significantly decreased (Figures 3A and 3B), indicating dimin-
ished tumor-vascular density. This decrease was consistent
with the changes in vessel morphology seen at the same time-
point (Figure 2B), suggesting a cumulative effect of EC apoptosis
over time.
To examine the kinetics of tumor-vascular disruption more
closely, we used noninvasive, near-infrared imaging of a fluores-
cent macromolecular blood-pool probe. Intravenous (i.v.)ll 22, 80–90, July 10, 2012 ª2012 Elsevier Inc. 83
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Figure 4. DR5-Mediated Vascular Disruption Is Independent of
TNFR Signaling
(A) LLC tumors (>500 mm3) grown inWT or TNFR1/2-double-KO (TNFR1/2/)
mice were dosed intraperitoneally with 10 mg/kg of Apo2L/TRAIL or PBS.
Tumors were examined macroscopically 24 hr after treatment for the
appearance of vascular disruption.
(B) Table summarizing the incidence of hemorrhage in tumors grown in
recipient mice with the indicated genotypes.
(C) LLC tumor cells were implanted in C57BL/6 WT or TNFR1/2-double-KO
mice. After a 24 hr treatment with Apo2L/TRAIL or PBS (control), tumors were
harvested and flow cytometry was used to measure cleaved caspase-3 in
tumor cells. Caspase-3 activation is represented as fold over control (PBS).
Error bars indicate the SEM. Student’s t test was used to calculate statistical
significance. N/S, not significant. Data in Figure 4 are representative of two or
more independent experiments.
Cancer Cell
DR5 Activation Disrupts the Tumor Vasculatureadministration of macromolecular probes enables longitudinal
assessment of vascular permeability, because probe distribution
within tumors is governed by endothelial permeability and the
differential rates of clearance between the vascular and intersti-
tial compartments (for further discussion see Figure S3). In
untreated tumor-bearing mice, fluorescence intensity within
tumors decreased exponentially following i.v. probe injection
(Figures 3C and 3D), consistent with the expected systemic84 Cancer Cell 22, 80–90, July 10, 2012 ª2012 Elsevier Inc.half-life of the probe. By contrast, in animals treated with
ApoL2/TRAIL 2 hr before probe injection, tumor-associated
fluorescence decreased initially, comparable to control, but
then increased between 2 and 6 hr. Both the timing and charac-
teristics of the phenotype were consistent with an acute change
in vascular permeability (Figure S3C), rather than vascular
normalization due to an antiangiogenic effect (Jain, 2005; McKe-
age and Baguley, 2010). Apo2L/TRAIL treatment of DR5-KO
tumor-bearing mice did not result in abnormal probe clearance,
confirming that the disruption of tumor-vascular integrity re-
quired stromal DR5. Together, these data suggest that Apo2L/
TRAIL induces DR5-dependent changes in the tumor vascula-
ture within 4 hr of treatment.
DR5-Mediated Tumor-Vascular Disruption Is
Independent of TNFR Signaling
In addition to proapoptotic signaling, engagement of DR5
under certain circumstances may activate nonapoptotic path-
ways, such as the nuclear factor-kB (NF-kB) cascade, which
promotes cytokine and chemokine production, among other
cellular effects (Wilson et al., 2009). Tumor necrosis factor
alpha (TNFa), often induced by NF-kB stimulation, has been
reported to trigger dramatic tumor-vascular effects (Corti and
Ponzoni, 2004; ten Hagen et al., 2008). This raised the pos-
sibility that the impact of DR5 activation on the tumor
vasculature might be exerted indirectly, via TNFa. To examine
this notion, we implanted TNF receptor (TNFR) 1 and 2 double-
KO mice with LLC tumors and treated them with Apo2L/
TRAIL. The appearance and incidence of tumor-vascular dis-
ruption induced by Apo2L/TRAIL in TNFR1/2-KO mice were
indistinguishable from those in WT mice, yet were absent in
DR5-KO recipients (Figures 4A and 4B). In accordance,
TNFR1/2 deficiency in the stromal compartment had no impact
on Apo2L/TRAIL-induced caspase-3 activation in tumor epithe-
lial cells (Figure 4C). These results indicate that Apo2L/TRAIL
exerts its tumor-vascular effects independently of TNFR
signaling.
Tumor-Vascular Disruption Is Independent of DR5
Expression in Malignant Cells
Our findings suggested that DR5 ligation on tumor ECs might
directly induce apoptotic death of these cells; alternatively, proa-
poptotic signaling in DR5-expressing malignant cells might
indirectly mediate the observed apoptotic outcome in tumor
ECs. To interrogate this, we generated methylcholanthrene
(MCA)-induced fibrosarcomas in WT and DR5-KO mice and es-
tablished cell lines from the resulting tumors. We confirmed
significant DR5 expression or its absence by flow cytometric
analysis of the corresponding tumor cell lines (Figure 5A). We
then generated WT or DR5-KOMCA tumors by implanting these
fibrosarcoma cells in WT or DR5-KO recipient mice. Induction of
tumor hemorrhage by Apo2L/TRAIL required DR5 expression
in the stroma, but not the malignant tumor-cell compartment
(Figure 5B; Figure S4). Immunostaining with anti-PLVAP and
anti-active caspase-3 antibodies confirmed proapoptotic sig-
naling in tumor ECs, regardless of DR5 expression status in the
malignant cells (Figures 5C and 5D). Hence, disruption of the
tumor vasculature by Apo2L/TRAIL occurs independently of
DR5 engagement in cancer cells.
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Figure 5. Effect of Apo2L/TRAIL on the Tumor Vasculature Is Independent of DR5 Expression in Malignant Cells
(A) Methylcholanthrene (MCA)-induced fibrosarcoma cell lines were derived from WT (DR5+/+) or DR5-KO (DR5/) C57BL/6 mice and assayed for DR5
expression by flow cytometry.
(B) Images are shown of DR5+/+ or DR5/ fibrosarcoma tumors, grown in C57BL/6 DR5+/+Rag2/ (top andmiddle panels), or C57BL/6 DR5/ (bottom panels),
recipients. Tumors were harvested at 24 hr post-treatment with Apo2L/TRAIL and compared with PBS-treated controls.
(C and D) Apoptosis in tumor vasculature of MCA-induced tumors. DR5+/+ (C) or DR5/ (D) MCA-induced fibrosarcoma cells were implanted in C57BL/6
DR5+/+Rag2/ recipients and treated with Apo2L/TRAIL (10 mg/kg) for 4 hr. Serial sections from tumors were stained with antibodies specific for PLVAP or
cleaved casapse-3 to localize endothelial and apoptotic cells, respectively. Scale bars, 100 mm. Data in Figure 5 are representative of two or more independent
experiments.
See also Figure S4.
Cancer Cell
DR5 Activation Disrupts the Tumor VasculatureDR5-Mediated Vascular Disruption Reduces Tumor
Growth
The induction of DR5-mediated apoptosis in tumor ECs sug-
gested that it might be possible to harness this activity for
therapeutic gain. To assess this, we compared the ability of
Apo2L/TRAIL to inhibit tumor growth in WT mice bearing either
DR5-expressing or DR5-deficient tumors. In vitro analysis of
caspase-8 and caspase-3/7 activation and loss of cell viability
confirmed a lack of proapoptotic signaling in DR5-KO MCA
tumor cells (Figure 6A). Consistent with the immunohistochem-
ical evidence (Figures 5C and 5D), both DR5-expressing and
DR5-KO fibrosarcomas showed significant caspase-3 activation
in vivo in response to Apo2L/TRAIL (Figure 6B). This result sug-
gested that the death of malignant cells occurred as an indirect
consequence of tumor-vascular disruption. Supporting this
hypothesis, the growth of pre-established fibrosarcomas pos-
sessing either DR5 genotype was significantly attenuated by
Apo2L/TRAIL (Figures 6C and 6D). Moreover, in both cases,
extensive hemorrhagic tumor necrosis occurred (Figure S4).
Thus, DR5-mediated apoptosis in tumor ECs can contribute to
antitumor efficacy in a manner that is distinct and separablefrom DR5-dependent malignant-cell apoptosis. We also evalu-
ated vascular density and morphology at an ‘‘end of study’’
time point (i.e., when control and Apo2L/TRAIL-treated tumors
had grown to similar size). Although overall vascular density
was significantly reduced in tumors exposed to Apo2L/TRAIL
as compared with controls, vascular morphology was indis-
tinguishable (Figures S5A and S5B). Hence, although repeat
dosing of Apo2L/TRAIL exerts a long-term effect on tumor-
vascular density, treatment cessation allows the tumor vascula-
ture to reform.
Consistent with its modest proapoptotic activity toward the
fibrosarcoma and LLC cell lines in vitro (Figure 6A; Figure S1C),
Apo2L/TRAIL did not induce significant proapoptotic signal-
ing in the malignant-cell compartment of corresponding
tumors in DR5-KO mice (Figure 6E; Figure S5C). Although DR5
status in the recipient mice did not affect tumor initiation or
growth (data not shown), antitumor activity of Apo2L/TRAIL
required DR5 expression in the stromal compartment (Figures
S5D and S5E). Therefore, in these particular models, DR5
engagement on tumor ECs may be the primary mechanism
mediating the inhibition of tumor growth by Apo2L/TRAIL. TheCancer Cell 22, 80–90, July 10, 2012 ª2012 Elsevier Inc. 85
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Figure 6. Vascular Disruption by Apo2L/TRAIL Contributes to Antitumor Effects In Vivo
(A) DR5+/+ or DR5/ fibrosarcoma cell lines were treated in vitro with a dose titration of Apo2L/TRAIL. Caspase-8 and caspase 3/7 activity was quantified 4 hr
after treatment using luminescent substrate assays. Cell viability was determined 24 hr after Apo2L/TRAIL treatment using an ATP-based Cell Titer Glo assay.
(B) DR5+/+ or DR5/ fibrosarcoma cell lines were grown in DR5+/+Rag2/ recipient mice, treated with a single dose (10 mg/kg) of Apo2L/TRAIL, and harvested
for immunohistochemical (IHC) staining with antibodies against cleaved caspase-3. Graph shows quantitation of cleaved caspase-3 IHC staining on tumor
sections from control (0 hr) or Apo2L/TRAIL-treated (24 hr) mice. The mean of n = 5 tumors for each group is plotted; error bars indicate the SEM. Student’s t test
was used to calculate statistical significance.
(C and D) C57BL/6 DR5+/+Rag2/ mice bearing wild-type (C) or DR5/ (D) MCA-induced tumors were treated with Apo2L/TRAIL five times per week for two
weeks, and tumor growth was compared with untreated controls. Error bars indicate the SEM (n = 8–10 mice/group). p values were calculated using Student’s t
test; asterisk indicates p < 0.01; double asterisks indicate p < 0.001.
(E) DR5+/+ MCA-induced fibrosarcoma cells were grown in DR5+/+ or DR5/ C57BL/6 mice. Tumors were harvested 24 hr after treatment with Apo2L/TRAIL,
and flow cytometry was used to measure cleaved caspase-3 in tumor cells. Caspase-3 activation is shown as fold increase over control (0 hr). Error bars indicate
the SEM (n = 3–5 mice/group). Data in Figure 6 are representative of two or more independent experiments.
See also Figure S5.
Cancer Cell
DR5 Activation Disrupts the Tumor Vasculaturelack of malignant-cell apoptosis in the absence of stromal DR5
could be attributed alternatively to a nonoptimal distribution of
the crosslinked ligand into the tumor in this context. To address
this, we used H2122 human lung carcinoma cells, which exhibit
strong sensitivity to Apo2L/TRAIL (Wagner et al., 2007). We
established H2122 tumor xenografts in Rag2-deficient mice
with DR5-WT or DR5-KO stromal compartments. In the pres-
ence of stromal DR5, but not in its absence, Apo2L/TRAIL
induced H2122 tumor hemorrhage similar to that seen in the
fibrosarcoma and LLCmodels (Figure S5F). Nonetheless, activa-
tion of caspase-3 in H2122 tumor cells was comparable in both
DR5 genotypic backgrounds (Figure S5G). Hence, antibody-
crosslinked Apo2L/TRAIL can access the malignant tumor cells
to induce apoptosis independently of stromal DR5 expression or
effects on the tumor vasculature. These data suggest that
DR5-mediated vascular disruption represents an alternative,
possibly complementary, mechanism of antitumor efficacy of
Apo2L/TRAIL.86 Cancer Cell 22, 80–90, July 10, 2012 ª2012 Elsevier Inc.Apo2L/TRAIL Disrupts the Tumor Vasculature
in a Genetic Model of Pancreatic Cancer
Our results demonstrated that DR5 engagement could disrupt
the tumor vasculature in murine syngeneic tumor models (Fig-
ures 2, 3, 4, and 5) as well as in mouse xenograft models of
human lung and breast cancer (Figure S5F; data not shown).
Genetically engineered mouse models of cancer have been
increasingly recognized for their ability to recapitulate many
aspects of human cancer, including pathogenesis and response
to therapy. Therefore, to assess more rigorously the ability of
Apo2L/TRAIL to disrupt tumor vessels, we turned to a previously
established, genetically engineered mouse model of pancreatic
ductal adenocarcinoma (Singh et al., 2010). Seven out of eight
(87.5%) tumors from KrasLSLG12D; p16/p19fl/fl; Pdx1-Cre
mice treated with a single dose of Apo2L/TRAIL showed ex-
tensive hemorrhage (Figures 7A and 7B), similar to that seen in
syngeneic or xenografted tumor models. Anti-PLVAP staining
confirmed tumor-vessel disruption in Apo2L/TRAIL-treated
Untreated Apo2L/TRAIL
Untreated Apo2L/TRAILA
B
C
Tumor: DR5+/+
Stroma: DR5+/+
Figure 7. Vascular Disruption by Apo2L/TRAIL in a Mouse Genetic
Model of Human Pancreatic Cancer
(A) Tumor-bearing KrasLSL-G12D; p16/19fl/fl; Pdx1-Cre mice were dosed
intraperitoneally with 10 mg/kg of Apo2L/TRAIL or PBS. Tumors were exam-
ined macroscopically 24 hr after treatment for the appearance of vascular
disruption.
(B) H&E staining of sections from pancreatic ductal adenocarcinomas re-
sected from Apo2L/TRAIL or untreated mice. Representative images show
widespread hemorrhaging observed in 7 of 8 tumors from mice treated with
Apo2L/TRAIL. Scale bars, 200 mm.
(C) Anti-PLVAP staining was used to visualize the tumor endothelium; repre-
sentative images show disrupted blood vessels in tumors from Apo2L/TRAIL-
treated but not in control mice. Scale bars, 50 mm.
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Figure 8. Analysis of DR5 Expression in Human Tumor Endothelial
Cells
(A) Representative sections from three separate human nonsmall cell lung
cancer (NSCLC) specimens with DR5 expression in the tumor endothelium.
Dashed boxes indicate areas shown at higher magnification (right panels).
Red arrows indicate focal DR5-positive tumor endothelial cells.
(B) Representative sections from normal human lung and kidney, respectively.
Scale bars, 50 mm.
See also Figure S6.
Cancer Cell
DR5 Activation Disrupts the Tumor Vasculaturemice (Figure 7C). The ability of Apo2L/TRAIL to trigger vascular
disruption in a range of tumor types and contexts supports the
potential relevance of this activity for treating human cancer.
Evidence for DR5 Expression in Human Tumor
Endothelial Cells
To evaluate the frequency of DR5 expression in ECs within
human tumors, we analyzed a panel of surgical tissue specimens
from nonsmall cell lung cancer (NSCLC) patients by DR5 immu-
nohistochemistry. Of 43 samples, four (10%) showed focal
regions of DR5 expression in the tumor endothelium (Figure 8A).
We also surveyed a panel of normal tissues from human and
mouse: With the exception of some staining in human stomach,
DR5 expression was not detected in the endothelium or in other
cell types of normal tissues (Figure 8; Figure S6). Consistent with
the lack of DR5 expression in nontumor vasculature, repeated
dosing of naive C57BL/6 mice with Apo2L/TRAIL did not signif-
icantly affect body weight or survival, despite some small, tran-
sient elevations in liver enzyme activity, detected in serum from
some of the animals (Figures S6C–S6E and data not shown).
These findings suggest that endothelial expression of DR5 is
present in a subset of human NSCLC tumors. In contrast, ex-
pression in normal tissues is rarely detected, permitting repeatedadministration of crosslinked Apo2L/TRAIL in mice without
significant adverse effects.
DISCUSSION
The current experimental paradigm for PARAs as cancer-
therapeutic agents is based on their ability to induce direct
cancer-cell apoptosis via DR5 and/or DR4 (Ashkenazi, 2002,
2008b; Johnstone et al., 2008). Yet, clinical studies with PARAs
to date have suggested that malignant cells are relatively refrac-
tory to death-receptor engagement, suggesting that various
mechanisms of apoptosis evasion may limit the efficacy of
such agents in patients with cancer (Yang et al., 2010). In theCancer Cell 22, 80–90, July 10, 2012 ª2012 Elsevier Inc. 87
Cancer Cell
DR5 Activation Disrupts the Tumor Vasculaturepresent study, we show that an oligomeric form of Apo2L/TRAIL,
which displays more potent agonistic activity toward DR5 and is
capable of engaging the murine receptor, can achieve antitumor
effects by directly perturbing the tumor vasculature. Oligomeric
Apo2L/TRAIL induced vascular disruption in several tumor
settings and models.
Our data suggest that DR5 activation in tumor ECs induces
apoptotic death of these cells, thereby compromising vascular
integrity and causing vessel congestion, intratumoral hemor-
rhage, decreased vascular density, and diminished tumor
growth. Several lines of evidence indicate that Apo2L/TRAIL
can act directly on the tumor stroma: First, its effects on the
vasculature and on tumor growth in the fibrosarcoma model
persisted even when DR5 was genetically ablated from the
malignant cell compartment. Conversely, the effects on the
tumor vasculature were abolished upon genetic ablation of
DR5 the stroma, diminishing antitumor efficacy in both the fibro-
sarcoma and LLC models. Second, Apo2L/TRAIL induced
significant levels of caspase-3 activation in tumor ECs prior to
engaging apoptosis in the malignant cell compartment. Consid-
ering that other stromal cells (e.g., immune infiltrates) did not
show appreciable DR5 expression, our data demonstrate the
ability of Apo2L/TRAIL to induce direct, DR5-dependent apo-
ptosis in tumor ECs.
Importantly, DR5-mediated vascular disruption exerted anti-
tumor activity even in the absence of DR5 in malignant cells,
thus highlighting the potential for attacking tumors that other-
wise might be expected to resist PARA therapy. Although
vascular disruption appears to be the primary mechanism for
antitumor effects in the fibrosarcoma and LLC models studied
here, this may not apply to all tumors. Indeed, direct effects of
PARAs on cancer cells are well established and further sup-
ported by the activity of Apo2L/TRAIL against H2122 human
xenografts in the absence of stromal DR5 expression and
tumor-vascular disruption. Thus, DR5-mediated perturbation of
the tumor vasculature may constitute an alternative, and per-
haps complementary, antitumor strategy to the current PARA-
based approach of directly inducing tumor-cell apoptosis.
Several vascular disrupting agents (VDAs) are in clinical devel-
opment for cancer treatment. However, there is concern that the
therapeutic utility of these agents might be limited by adverse
events, such as on-target effects against normal vasculature,
as well as a lack of efficacy (Heath and Bicknell, 2009; Lara
et al., 2011; Lorusso et al., 2011; McKeage and Baguley, 2010).
Certain effects of Apo2L/TRAIL on the tumor vasculature—
namely, the rapid disruption of existing vessels and ensuing in-
tratumoral hemorrhage—are similar to those of other VDAs.
However, despite these similarities, there are key differences
in the mechanisms of action of Apo2L/TRAIL versus known
VDAs. One class of VDAs, including combretastatin and its
analogs, acts primarily by inhibiting tubulin polymerization and
inducing changes in EC shape (McKeage and Baguley, 2010;
Siemann et al., 2009). Although its specific molecular target is
unknown, another clinically tested VDA, the flavonoid ASA404,
induces vascular permeabilization and EC apoptosis via TNFa-
dependent mechanisms (Baguley, 2011). In contrast to these
agents, Apo2L/TRAIL disrupts the tumor vasculature strictly
through direct DR5-mediated apoptosis in tumor ECs. This
mechanistic difference may have important implications for88 Cancer Cell 22, 80–90, July 10, 2012 ª2012 Elsevier Inc.both safety and efficacy outcomes in patients. Nevertheless,
additional studies will be necessary to understand more fully
the impact of DR5 activation in tumor ECs and the longer-term
effects on vascular function.
An additional consideration is that specific PARAs exhibit
differences in potency that may affect their biological activity
and potential toxicity. The enhanced activity of oligomeric
Apo2L/TRAIL toward mouse DR5 suggests that this form of
the protein may better mimic the endogenous transmembrane
ligand. It is possible that the noncrosslinked trimeric Apo2L/
TRAIL molecule represented by dulanermin, as well as DR5
agonistic antibodies, although active against malignant cells,
do not achieve the signaling threshold required to induce signif-
icant apoptosis in tumor ECs. Thus, variants of PARAs with
greater potency might display stronger vascular disrupting
activity. Although more potent variants may not be as well toler-
ated as dulanermin (Lawrence et al., 2001), the lack of systemic
toxicity in mice with the oligomeric Apo2L/TRAIL used here is
encouraging, and suggests that a significant therapeutic window
may be achievable. This is further supported by the apparent
absence of DR5 expression in most normal vasculature and
tissues. However, more focused studies on the nontumor vascu-
lature, quiescent or inflamed, may reveal additional examples of
DR5modulation besides the tumor stroma. Regardless, any clin-
ical development of more potent PARAs would necessitate
extensive testing in animals, including nonhuman primates, to
exclude potential side effects on normal tissues including the
vasculature.
Only a minority (10%) of human NSCLC specimens showed
endothelial DR5 expression. However, given the very high prev-
alence of this lethal malignancy, our data suggest significant
impact for potential clinical translation and provide a compelling
rationale for assessing endothelial DR5 expression in other
human cancers. Furthermore, it will be interesting to determine
what specific features of the tumor microenvironment drive
endothelial DR5 expression and whether DR5 levels can be
manipulated by certain combinatorial treatment regimes. To
date, clinical efficacy with PARAs has not been observed in
unselected patients, with the exception of some individual
subjects (Ashkenazi and Herbst, 2008; Yang et al., 2010). In
future clinical studies, it will be important to assess more specif-
ically whether DR5 expression in tumor ECs correlates with
responsiveness to PARAs, and whether efficacy in individual
patients is associated with tumor-vascular disruption.
In conclusion, our studies uncover DR5-mediated proapop-
totic signaling in tumor ECs. We propose that PARAs may act
as a unique class of tumor-selective vascular disruption agents,
even for tumors in which themalignant cell compartment is resis-
tant to direct apoptosis induction via DR5.EXPERIMENTAL PROCEDURES
Mouse Models
C57BL/6 (wild-type) mice were obtained from the Jackson Laboratory, and
C57BL/6.Rag2/ mice were obtained from Taconic, Inc. C57BL/6.DR5/
(Diehl et al., 2004), C57BL/6.TNFR1/TNFR2/, Rag2/;DR5/ and
KrasLSLG12D; p16/p19fl/fl; Pdx1-Cre (Singh et al., 2010) mice were bred
and maintained at Genentech, Inc. under specific pathogen-free conditions.
All animal experiments were reviewed and approved by the Institutional Animal
Care and Use Committee (IACUC) at Genentech, Inc.
Cancer Cell
DR5 Activation Disrupts the Tumor VasculatureHuman Tissue Samples
Archival formalin fixed paraffin embedded (FFPE) tissue specimens of
nonsmall cell lung cancer (NSCLC) were collected and used in this study in
accordance with the protocol (APM4074 g) approved by the Institutional
Review Board of Kaiser Permanente Medical Center, (Vallejo CA and Portland,
OR), Ohio State University (Columbus, OH), Medical College of Wisconsin
(Milwaukee WI), and M. D. Anderson Cancer Center (Houston TX), and written
informed consent was obtained from patients in all cases at time of enrollment.
Normal tissue specimens were purchased from Biomax Inc., (Rockville, MD).
In all analyses, a slide was H&E stained and verified by a board-certified
pathologist.
Fibrosarcoma Tumor Initiation
C57BL/6 (wild-type) or C57BL/6.DR5/ mice were inoculated subcutane-
ously in the hind flank with 200 mg of methylcholanthrene (MCA) (Sigma-
Aldrich) in 0.1 ml of corn oil, as previously described (Koebel et al., 2007).
Mice were assessed weekly for tumor development from 90 days after MCA
treatment.
In Vivo Dosing
Dulanermin (trimeric Apo2L/TRAIL) and recombinant soluble Flag-tagged
human Apo2L/TRAIL was prepared according to a published method (Ashke-
nazi et al., 1999; Kischkel et al., 2000). Tumor-bearing mice were dosed intra-
peritoneallywith 60mg/kgof dulanermin, or 10mg/kgof Apo2L/TRAIL followed
by 10 mg/kg of the anti-Flag antibody (M2) (Sigma). For tumor growth studies
and the end-of-study experiment in Figure S5, mice were dosed with 1 or 2
cycles of Apo2L/TRAIL (10 mg/kg) as indicated. Each cycle consisted of
5 days of consecutive treatment,with 2 days of no treatment in betweencycles.
Cell Lines and Tumor Transplant Models
Lewis lung carcinoma, fibrosarcoma, and H2122 cells were maintained in
RPMI medium supplemented with L-glutamine and 10% fetal bovine serum
(FBS) under conditions of 5%CO2 at 37
C.Micewere injected subcutaneously
with 5 3 106 cancer cells. Tumors were measured in two dimensions using a
caliper. Tumor volume was calculated using the formula: V = 0.5a3 b2, where
a and b are the long and the short diameters of the tumor, respectively.
Additional details are available in Supplemental Experimental Procedures.
Cell Viability and Caspase-3 Assays
Cell viability following Apo2L/TRAIL treatment was determined in vitro using
the Cell-titer Glo cell viability assay (Promega). Caspase-3/7 or 8 activity
was measured in vitro using the Caspase-Glo 3/7 or Caspase-Glo 8 assay
(Promega), according to the manufacturer’s instructions. For in vitro viability
and caspase assays, Apo2L and M2 were combined sequentially at a 1:1
molar ratio. Ex vivo caspase-3 processing in tumor cells was monitored by
flow cytometry using the cleaved caspase-3-specific antibody (clone C92-
605, BD PharMingen). Caspase-3 activation is represented as a fold-increase
relative to control treated mice.
Immunohistochemistry for Mouse Specimens
Primary antibodies were used at 10 mg/ml for mouse DR5 (clone MD5-1,
BD Biosciences; Franklin Lakes, NJ), 2 mg/ml for PLVAP (clone MECA-32,
BD Biosciences, NJ), and 0.06 mg/ml for cleaved caspase 3 (Asp175)
(Cell Signaling Technologies; Danvers, MA). Quantitation of caspase-3 and
PLVAP immunostaining and additional details are described in Supplemental
Experimental Procedures.
In Vivo Near Infrared Fluorescence Imaging
Two hr after treatment with Apo2L/TRAIL or PBS, mice (n = 3–5/
treatment group) were injected intravenously with the fluorescent blood pool
marker AngioSense680IVM (PerkinElmer). The temporal distribution of
AngioSense680IVM within tumors and neighboring tissue was measured by
visualizing fluorescence (650 nm excitation/700 nm emission) with a Kodak
4000 FX Pro imaging system (CareStream Health) and quantifying fluores-
cence intensities within regions of interest placed over tumor or adjoining
tissue normalized to time = 0, (IROIt = x IBG) / (IROIt = 0 IBG). At each indicated
time point, animals were anesthetized under isoflurane, with body temperature
maintained at 37C, and were imaged.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at http://dx.doi.org/10.1016/j.ccr.2012.05.014.
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